"The U.S. Food and Drug Administration today approved Vimizim (elosulfase alfa), the first FDA-approved treatment for Mucopolysaccharidosis Type IVA (Morquio A syndrome). Morquio A syndrome is a rare, autosomal recessive lysosomal storage disease "...
(Generic versions may still be available.)
Actisite Side Effects Center
Medical Editor: John P. Cunha, DO, FACOEP
Actisite (tetracycline hydrochloride) Periodontal Fiber is an antibiotic used as an adjunct to scaling and root planing for reduction of pocket depth and bleeding on probing in patients with adult periodontitis. The brand name Actisite is discontinued, but generic versions may be available. Common side effects of Actisite (tetracycline hydrochloride) include:
- discomfort on fiber placement and local redness following removal,
- tongue discoloration, sore throat, or
Actisite fiber provides continuous release dosing of tetracycline for 10 days. At the end of 10 days of treatment, all fibers must be removed. Actisite may interact with other drugs. Tell your doctor all medications and supplements you use. During pregnancy, Actisite should be used only if prescribed. This drug passes into breast milk when taken in other forms. It is unknown if it passes into breast milk when used as periodontal fiber. Consult your doctor before breastfeeding.
Our Actisite (tetracycline hydrochloride) Periodontal Fiber Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
What is Prescribing information?
The FDA package insert formatted in easy-to-find categories for health professionals and clinicians.
Actisite FDA Prescribing Information: Side Effects
Actisite (tetracycline periodontal) fiber has been studied in 1437 patients distributed as follows over pivotal, controlled, and open- label studies.
In controlled and open-label trials patients, the following adverse reactions have been reported in less than 1% of patients: oral candidiasis, glossitis, possible allergic response, staining of the tongue, severe gingival inflammation, throbbing pain, pain following placement in an abscessed area, and minor throat irritation.
Read the entire FDA prescribing information for Actisite (Tetracycline Periodontal)
Additional Actisite Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.